Neurofilament heavy chain and chitinase 3-like 1 as markers for monitoring therapeutic response in multiple sclerosis
Language English Country Netherlands Media print-electronic
Document type Journal Article, Observational Study
PubMed
39383686
DOI
10.1016/j.msard.2024.105915
PII: S2211-0348(24)00491-7
Knihovny.cz E-resources
- Keywords
- Chitinase 3-like 1, ELISA, Multiple sclerosis, Neurofilament heavy chain,
- MeSH
- Biomarkers * blood MeSH
- Adult MeSH
- Outcome Assessment, Health Care MeSH
- Immunologic Factors administration & dosage pharmacology MeSH
- Middle Aged MeSH
- Humans MeSH
- Follow-Up Studies MeSH
- Neurofilament Proteins * blood MeSH
- Prospective Studies MeSH
- Chitinase-3-Like Protein 1 * blood MeSH
- Multiple Sclerosis blood drug therapy MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Names of Substances
- Biomarkers * MeSH
- CHI3L1 protein, human MeSH Browser
- Immunologic Factors MeSH
- neurofilament protein H MeSH Browser
- Neurofilament Proteins * MeSH
- Chitinase-3-Like Protein 1 * MeSH
AIMS: The aim of this study was to evaluate the association of serum neurofilament heavy chain (sNfH) and chitinase 3-like 1 (sCHI3L1) with treatment response and disease activity in multiple sclerosis (MS). METHODS: This single-center, prospective, observational cohort study was conducted at the MS Centre, University Hospital Ostrava, Czech Republic, from May 2020 to August 2023. sNfH and sCHI3L1 were determined using ELISA. A mixed-effects linear model with a log-transformed outcome variable was applied. RESULTS: We analyzed 459 samples from 57 people with MS. Patients were sampled an average of 8.05 times during 21.9 months of follow-up. Those experiencing a relapse at sampling had a sNfH concentration 50 % higher than those in remission (exp(β) 1.5, 95 % CI 1.15-1.96). A longer duration of treatment was associated with lower sNfH (exp(β) 0.95, 95 % CI 0.94-0.96). Patients switched from low- to high-efficacy disease-modifying therapies (DMTs) had higher sNfH than patients treated with low-efficacy DMTs only (exp(β) 1.95, 95 % CI 1.35-2.81). Higher sCHI3L1 was associated with older age (exp(β) 1.01, 95 % CI 1.00-1.02) and longer DMT use (exp(β) 1.01, 95 % CI 1.00-1.02). sCHI3L1 values were not associated with relapse at the time of sampling, renal function, sex, or type of DMT. CONCLUSION: In contrast to sCHI3L1, sNfH may be a potential biomarker for monitoring treatment response and confirming clinical relapse in MS. Further research is needed to determine the long-term dynamics of sNfH and develop related treatment strategies.
University Hospital Ostrava Department of Hematooncology Ostrava Czech Republic
University of Ostrava Department of Clinical Neurosciences Ostrava Czech Republic
References provided by Crossref.org
